| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 270/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| product name | Valsartan |
| CAS NO. | 137862-53-4 |
| Specification | 99% |
| Appearance | white powder |
| Package | 1KG/Bag,25Kg/drum |
| MOQ | 1Kg |
Valsartan is an angiotensin II receptor antagonist antihypertensive drug. The drug blocks the type I (AT1) receptor of angiotensin II, increases the plasma level of angiotensin II, stimulates the unblocked AT2 receptor, and counteracts the AT1 receptor, thereby achieving the effect of dilating blood vessels and lowering blood pressure. In the United States, valsartan is a drug used to treat hypertension, congestive heart failure, and post-myocardial infarction. Diovan valsartan, developed and produced by Ciba-Geigy of Switzerland, obtained relevant patents in the United States and Europe in 1995 and 1996 respectively, and was first launched in Germany in July 1996, and has since been launched in Europe, the United States, and Japan. Ciba-Geigy and Sandoz merged to form Novartis in 1996. Valsartan has the characteristics of long-lasting and stable blood pressure lowering effect and few toxic side effects.
| Items | Standards | Results |
| Appearance | white powder | Complies |
| Specification | 99% | 99.20% |
| Loss on Drying | ≤ 5.0% | Complies |
| Heavy Metal | ≤ 10.0 mg/kg | Complies |
| Pb | ≤ 2.0 mg/kg | Complies |
| As | ≤ 1.0 mg/kg | Complies |
| Hg | ≤ 0.1 mg/kg | Complies |
| Total Plate Count | ≤ 1000cfu/g | Complies |
| Yeast&Mold | ≤ 100cfu/g | Complies |
| E.coil | Negative | Negative |
| Salmonella | Negative | Negative |
| Conclusion: in conformity with the enterprise standard | ||
Uses
Antihypertensive drugs. Valsartan is an angiotensin II (Ang II) receptor antagonist that can selectively block the binding of Ang II to the AT1 receptor (its specific antagonism of the AT1 receptor is about 20,000 times greater than that of AT2), thereby inhibiting vasoconstriction and the release of aldosterone, producing a hypotensive effect.
Valsartan is a non-peptide, orally effective angiotensin II (AT) receptor antagonist. It is highly selective for type I receptors (AT1) and can competitively antagonize without any agonistic effect. It can also inhibit the release of aldosterone from adrenal glomerular cells mediated by AT1 receptors, but valsartan has no inhibitory effect on the release caused by potassium, which also shows the selective effect of valsartan on AT1 receptors. In vivo tests on various types of hypertensive animal models have shown that valsartan has a good antihypertensive effect and has no significant effect on cardiac contractile function and heart rate. It has no antihypertensive effect on animals with normal blood pressure. It is rapidly absorbed after oral administration, with a bioavailability of 23%. The binding rate with plasma proteins is 94% to 97%. About 70% is excreted from feces and 30% is excreted from the kidneys, all in their original form. T1/2β is about 9 hours. Taking it with food does not affect its efficacy. The blood pressure of hypertensive patients begins to drop 2 hours after taking it once, and the maximum antihypertensive effect is reached after 4 to 6 hours. The antihypertensive effect can last for 24 hours. The blood pressure reduction reaches its maximum effect after 2 to 4 weeks of continuous medication. It can be used in combination with hydrochlorothiazide to enhance the antihypertensive effect.
){kind=link}